Aerococcus urinae - A potent biofilm builder in endocarditis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 26 11 2019
accepted: 01 04 2020
entrez: 24 4 2020
pubmed: 24 4 2020
medline: 22 7 2020
Statut: epublish

Résumé

The diagnosis of infective endocarditis (IE) remains a challenge. One of the rare bacterial species recently associated with biofilms and negative cultures in infective endocarditis is Aerococcus urinae. Whether the low number of reported cases might be due to lack of awareness and misidentification, mainly as streptococci, is currently being discussed. To verify the relevance and biofilm potential of Aerococcus in endocarditis, we used fluorescence in situ hybridization to visualize the microorganisms within the heart valve tissue. We designed and optimized a specific FISH probe (AURI) for in situ visualization and identification of A. urinae in sections of heart valves from two IE patients whose 16S rRNA gene sequencing had deteced A. urinae. Both patients had a history of urinary tract infections. FISH visualized impressive in vivo grown biofilms in IE, thus confirming the potential of A. urinae as a biofilm pathogen. In both cases, FISH/PCR was the only method to unequivocally identify A. urinae as the only causative pathogen for IE. The specific FISH assay for A. urinae is now available for further application in research and diagnostics. A. urinae should be considered in endocarditis patients with a history of urinary tract infections. These findings support the biofilm potential of A. urinae as a virulence factor and are meant to raise the awareness of this pathogen.

Identifiants

pubmed: 32325482
doi: 10.1371/journal.pone.0231827
pii: PONE-D-19-32798
pmc: PMC7180067
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0231827

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2019 Aug 27;14(8):e0221786
pubmed: 31454398
Appl Environ Microbiol. 1990 Jun;56(6):1919-25
pubmed: 2200342
J Clin Microbiol. 2000 Apr;38(4):1703-5
pubmed: 10747177
J Med Microbiol. 1976 Aug;9(3):275-302
pubmed: 785000
FEMS Immunol Med Microbiol. 2012 Jul;65(2):127-45
pubmed: 22469292
NPJ Biofilms Microbiomes. 2016 Jun 22;2:16012
pubmed: 28721248
Infection. 2002 Oct;30(5):310-3
pubmed: 12382093
Int J Syst Evol Microbiol. 2014 Apr;64(Pt 4):1229-36
pubmed: 24421273
Lab Med. 2014 Summer;45(3):e101-3
pubmed: 25135044
Eur Heart J. 2015 Nov 21;36(44):3075-3128
pubmed: 26320109
Lancet Infect Dis. 2012 Oct;12(10):774-80
pubmed: 22951600
Clin Infect Dis. 2010 Jul 15;51(2):131-40
pubmed: 20540619
Clin Infect Dis. 1995 Oct;21(4):943-7
pubmed: 8645844
Int J Syst Evol Microbiol. 2001 Mar;51(Pt 2):683-686
pubmed: 11321115
Int J Syst Bacteriol. 1999 Jul;49 Pt 3:1125-8
pubmed: 10425770
Clin Microbiol Infect. 2010 Jun;16(6):767-73
pubmed: 19694763
Scand J Infect Dis. 1991;23(6):717-21
pubmed: 1815334
Int J Syst Evol Microbiol. 2001 Mar;51(Pt 2):475-479
pubmed: 11321093
BMJ Case Rep. 2016 Jul 20;2016:
pubmed: 27440847
J Microbiol Methods. 2000 Jul;41(2):85-112
pubmed: 10991623
J Antimicrob Chemother. 2001 Nov;48(5):653-8
pubmed: 11679554
J Clin Microbiol. 2013 Apr;51(4):1303-4
pubmed: 23390276
Int J Antimicrob Agents. 2016 Sep;48(3):271-6
pubmed: 27451085
Crit Rev Microbiol. 2017 May;43(3):263-293
pubmed: 28129707
Open Microbiol J. 2016 Mar 10;10:27-31
pubmed: 27014376
J Clin Microbiol. 1991 May;29(5):1049-53
pubmed: 2056040
Microbiology. 1998 Sep;144 ( Pt 9):2459-67
pubmed: 9782493
Infect Immun. 2010 Oct;78(10):4268-75
pubmed: 20696834
Infection. 2016 Apr;44(2):167-73
pubmed: 26119199
J Gen Microbiol. 1953 Jun;8(3):475-80
pubmed: 13061751
BMC Infect Dis. 2018 Oct 17;18(1):522
pubmed: 30333008
J Gen Microbiol. 1992 Feb;138(2):401-5
pubmed: 1373437

Auteurs

Berrin Yaban (B)

Biofilmzentrum, Dept. of Microbiology, Infectious Disease and Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Judith Kikhney (J)

Biofilmzentrum, Dept. of Microbiology, Infectious Disease and Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
MoKi Analytics GmbH, Marienplatz, Berlin, Germany.

Michele Musci (M)

Dept. of Congenital Heart Surgery-Pediatric Heart Surgery, German Heart Center Berlin, Berlin, Germany.

Annett Petrich (A)

Biofilmzentrum, Dept. of Microbiology, Infectious Disease and Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Julia Schmidt (J)

Biofilmzentrum, Dept. of Microbiology, Infectious Disease and Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
MoKi Analytics GmbH, Marienplatz, Berlin, Germany.

Maria Hajduczenia (M)

Biofilmzentrum, Dept. of Microbiology, Infectious Disease and Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Felix Schoenrath (F)

Dept. of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.

Volkmar Falk (V)

Dept. of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
Dept. of Cardiothoracic Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Annette Moter (A)

Biofilmzentrum, Dept. of Microbiology, Infectious Disease and Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
MoKi Analytics GmbH, Marienplatz, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH